帕罗西汀治疗糖尿病伴发焦虑抑郁障碍对照研究  

A control study of paroxetine in diabetes accompanying anxiety-depression

作　　者：孙洪军[1] 

机构地区：[1]通辽市神经精神病医院,内蒙古通辽028000

出　　处：《临床心身疾病杂志》2007年第1期11-12,共2页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨帕罗西汀治疗糖尿病伴发焦虑抑郁障碍的临床疗效。方法将36例糖尿病伴发焦虑抑郁障碍患者随机分为研究组与对照组各18例,均给予糖尿病常规治疗。研究组联用帕罗西汀治疗,对照组联用安慰剂治疗,疗程8 w。采用焦虑自评量表,抑郁自评量表评定焦虑抑郁症状改善情况,并与国内常模进行对比分析。结果治疗前两组焦虑自评量表,抑郁自评量表评分均显著高于国内常模(P<0.05),有并发症与无并发症者、空腹血糖>10 mmol.L-1与<10 mmol.L-1者、胰岛素治疗与非胰岛素治疗者的总分均有显著性差异(P均<0.05);治疗8 w末焦虑自评量表、抑郁自评量表评分均较治疗前显著下降(P<0.05),研究组较对照组下降更显著(P<0.05)。结论糖尿病患者存在明显的焦虑抑郁障碍,帕罗西汀疗效显著,依从性好。Objective To explore the curative effect of paroxetine in diabetes accompanying anxiety-depression. Methods 36 subjects were randomly divided into research group（n= 18） receiving conventional therapy plus paroxetine and control group（n= 18） plus placebo for 8 weeks. Symptoms＇ improvement was assessed with the SAS and SDS respectively and compared with national norm. Results Before treatment, scores of both the SAS and SDS were significantly higher in both groups than in national norm（P〈0.05）, and there were significant differences in total scores between patients with or without complications, ones with blood-fasting sugar〉10mmol/L or 〈10mmol/L and ones receiving insulin treatment or non-insulin treatment（all P〈0.05）; at the end of the 8th week, scores of both the SAS and SDS notably decreased compared with pre-treatment（P〈0.05）, and the research group decreased more significantly than the control group did（P〈0.05）. Conclusion Diabetics has visible anxiety and depression, paroxetine has notable curative effect and better compliance.

关 键 词：心身疾病 糖尿病 焦虑 抑郁 帕罗西汀 

分 类 号：R749.92[医药卫生—神经病学与精神病学]